• A Novel Immunosuppression Intervention for the Treatment of Amyotrophic Lateral Sclerosis
Massachusetts General Hospital is seeking individuals to participate in a research study enrolling under the direction of James Berry, MD.

The purpose of the research study is to determine whether drugs that suppress the immune system will slow the progression of Amyotrophic Lateral Sclerosis (ALS) in participants with this disease. These drugs will lower your ability to fight infections. While taking the study drug, participants will be asked to complete several tests, including blood draws and lumbar punctures, and a questionnaire. These procedures will be performed several times over the course of about twelve months. The researchers hope to learn more about ALS and its treatment from this study.

Participants must be at least 18 years of age. Participants should be located close to the study site and be able to follow study tasks. If interested, please contact study coordinator Owen O’Connor at 617-726-5059 or e-mail him at OJOConnor@partners.org. You may also contact the Coordination Center via the Northeast ALS Consortium (NEALS) for more information about this study at mghneuroclinicaltrialsunit@partners.org or toll free at 1-877-458-0631.
Institution  –  MGH - Massachusetts General Hospital, Boston, MA
Principal Investigator  – James D Berry, MD
Enrollment Information
For further information about enrolling a patient in this trial, contact the person below.
Name  – Anne E Bozik, CRC
Phone  – 617-724-4246